Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study - Test2 - elhamkhani - TriplyDB

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

http://www.wikidata.org/entity/Q24563021

about

Hypomethylating agents for patients with myelodysplastic syndrome Thrombopoietin mimetics for patients with myelodysplastic syndromes Low dose cytarabine monotherapy for myelodysplastic syndromes Hypomethylating agents for patients with myelodysplastic syndrome Safety and efficacy of azacitidine in myelodysplastic syndromes Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy A decade of exploring the cancer epigenome - biological and translational implications An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents A phase 2 study of vorinostat in acute myeloid leukemia A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics The blind men and the AML elephant: can we feel the progress?Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes Characterization of DNA Methylation in Circulating Tumor Cells Spotlight on decitabine for myelodysplastic syndromes in Chinese patients Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications The complexity of epigenetic diseases Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Targeting caspases in cancer therapeutics Beyond hypomethylating agents failure in patients with myelodysplastic syndromes The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells Infections in myelodysplastic syndromes Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy Myelodysplastic syndromes: what do hospitalists need to know?Clinical Results of Hypomethylating Agents in AML Treatment A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

P2860

Q24186276-AEC65227-6518-4B8B-B2F4-BEAF505470D6 Q24198060-CF2789B2-518D-4694-8EE3-10466F5C0D59 Q24234789-B22CB241-F4BB-4E29-9F10-DADE49024731 Q24236549-2B7FD6B8-6FAB-4CA8-95B8-B8C67D0ABE51 Q24596561-EE878E34-A4B6-4AE4-BD82-3DB32A9C9337 Q24597616-E01E508E-F8E8-4836-9E20-0C875D9053D5 Q24599447-E3FC54F1-98B7-49EF-BB59-8BC0EE277669 Q24605618-C59B3033-C002-4F76-8395-17FE74BFB8FC Q24608659-C8D5C256-8393-4BCE-9BBA-064E092F18DC Q24609974-E23C1A36-BE71-4BBA-91BA-016B0679FD82 Q24614467-D7543938-9D4D-486B-9424-3009E05A0F9A Q24622700-5750B04F-AA85-4A3A-8FEB-AD60CFAB59D3 Q24632949-7D651702-5A9F-43DE-AAAC-527B82FDC0E4 Q24633763-BC0973EE-A2B6-42BD-A816-9A5B4C15C622 Q24643266-469512E3-ADA2-45A1-A3BF-D72E296D3275 Q26743743-AAE96CB4-7C18-401B-A0EE-0D3E8F37260E Q26744080-2F5ABCED-A754-4D79-A005-2C8AD0BA86BB Q26745731-F0628A5C-F13D-48A5-853D-F88F3CC33E1C Q26749421-B067A71E-A5D2-4A9D-8482-F4F8D11D6A12 Q26749614-9DA3F70E-D1C4-459B-95C4-88267A2A9998 Q26749870-B72D3E70-6BC6-460C-9D6F-62D75E57BF94 Q26767183-AB16E563-79A0-4B86-BE4E-57BCBCD1823E Q26778427-9882257A-F6BB-4069-9D3E-773F92B56E38 Q26778454-3D6DAFAD-4644-4CBA-AE2B-FF1B2B14A334 Q26783490-42094DB1-59A9-4F93-B405-DFDA38AD03B9 Q26784416-121C9556-8587-495B-9323-89E2DDF5E8E2 Q26796240-AA242803-2D71-4DC2-BAEF-A0602577C6B5 Q26801573-D0A17EF9-4B64-491E-82F1-A55A11FB772E Q26821986-B3B3CCFE-8CFE-4B62-95C4-B352C18F0909 Q26827079-A2CD8894-5E97-4587-913F-A7AF36AF6EEB Q26828751-CE319A72-82B1-481A-B431-88535877BEB7 Q26829132-907E9BF9-E09E-4506-A289-4961724BF671 Q26851510-4039B92F-019C-4FF6-8EA5-7532509E316F Q26859275-F6156F29-FC50-45E3-B879-4A096909315C Q26863610-AA47AD4F-EE2A-4B57-B392-A538B6087094 Q26865149-21BB12D9-6A71-490F-BE44-2C8D07375B71 Q27010653-546CC99B-0BA1-4E75-915A-0BFE380F1DF4 Q27011372-53ABD534-88EC-40DB-B6E4-A0A390A92A3B Q27022725-877E0FB6-28ED-442D-B878-A499FB8C5349 Q27024786-05A364E4-8FBD-40F6-9266-21AA4212FC50

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

http://www.wikidata.org/entity/Q24563021

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Efficacy of azacitidine compar ...... d, open-label, phase III study

@ast

Efficacy of azacitidine compar ...... d, open-label, phase III study

@en

Efficacy of azacitidine compar ...... d, open-label, phase III study

@nl

type

label

Efficacy of azacitidine compar ...... d, open-label, phase III study

@ast

Efficacy of azacitidine compar ...... d, open-label, phase III study

@en

Efficacy of azacitidine compar ...... d, open-label, phase III study

@nl

prefLabel

Efficacy of azacitidine compar ...... d, open-label, phase III study

@ast

Efficacy of azacitidine compar ...... d, open-label, phase III study

@en

Efficacy of azacitidine compar ...... d, open-label, phase III study

@nl

P1433

Q24563021-48AF2793-7531-4603-A74A-1F1C89D8F64C

P1476

Q24563021-4534400A-FDEE-4CB4-A400-4DC779662A99

P2093

Q24563021-0B010C4E-8222-4B98-B4B0-A21BEF5E3B14

Q24563021-265DE764-0E2B-4E41-BCEE-4A079DF49699

Q24563021-38C4340D-4CC3-4E4D-AF83-5674EB65A909

Q24563021-422DEC56-D9F6-4314-81AC-72E40A991A09

Q24563021-7F8AA314-2617-4289-8999-C9A5DF5BD96C

Q24563021-873DBCA3-4FE0-4223-9A9B-1E85A0BED4BE

Q24563021-9296D231-9B02-4F4C-A6C8-EE41C9173E89

Q24563021-9AD2B011-E557-4EF4-9F41-AFD608B2DF4B

Q24563021-A89C24FF-9F4A-4EC9-8162-9B37E8D72A77

Q24563021-C801CF93-1005-40CC-89D4-DC2C2AABD8B0

P2860

Q24563021-19950E07-BE39-42FD-B864-1B10173C05E1

Q24563021-2907743D-72E1-4FD5-8D9E-C41D231F598C

Q24563021-39598B46-EC64-4D27-A56C-496CFA3195CC

Q24563021-3BD1AD92-04B7-44F9-B5D0-CEF25522B572

Q24563021-3CB432AB-F553-407A-ADCB-E23D9743E9AD

Q24563021-431278BB-F349-47B5-AC2E-C68AB37DDF89

Q24563021-4D192EEF-5F63-4712-82FA-F8020EDD01D4

Q24563021-54C3416B-3491-47FB-9471-48FC426ED6DB

Q24563021-5518B08C-3B4E-4EAA-AA01-907E81307706

Q24563021-5F1A0BA5-CA9E-40B1-930A-15CCD44492E5

P304

Q24563021-B9910240-C676-4BB0-AC39-A4D07AA26A83

P31

Q24563021-8861C20D-A8C8-4D19-A2D3-0E56F8D7EE1C

P3181

Q24563021-34B58F6B-BD43-4522-9EE3-3F7E355611CF

P356

Q24563021-AB6F9945-A827-4A30-9FE2-2BE666D63163

P407

Q24563021-6869919F-A43E-440C-B3E3-88BD6A8C7A90

P433

Q24563021-8B3D4800-CA79-4618-AFE3-F20B45202335

P478

Q24563021-E3829ACF-73C4-4EFE-B156-44A28D85BD94

P50

Q24563021-0A8B21BA-B63A-4A2A-A462-135F9C95071D

Q24563021-2170C77A-D365-4826-902E-904144298A36

Q24563021-29895C03-CA62-4DBE-AE88-96F35E641A72

Q24563021-2DD9CE5C-8AA3-4DC4-B45D-7625D1931229

Q24563021-A885DE99-D14C-417E-857E-75BE63520814

Q24563021-AD35365C-3492-4F23-A833-6B7D715E1E7C

Q24563021-C2ACFE03-E14B-4E43-A358-671B8B7AA80F

Q24563021-D66C08CE-A063-4179-B063-15E170C83472

P577

Q24563021-ADD4D442-57AB-4664-B27B-E5ED58FC973A

P5875

Q24563021-017E9E19-54E0-43F4-A09F-CFD9FF4CEFA7

P698

Q24563021-436E79DC-BB47-403C-8B93-D053B2977621

P932

Q24563021-D51B1F7A-152C-4C66-9176-6831931502B8

P3181

P356

S1470-2045(09)70003-8

P1433

The Lancet Oncology

P1476

Efficacy of azacitidine compar ...... d, open-label, phase III study

@en

P2093

Carlo Finelli

http://www.w3.org/2001/XMLSchema#string

Cl Beach

http://www.w3.org/2001/XMLSchema#string

David McKenzie

http://www.w3.org/2001/XMLSchema#string

Eva Hellstrom-Lindberg

http://www.w3.org/2001/XMLSchema#string

Ghulam J Mufti

http://www.w3.org/2001/XMLSchema#string

Jay Backstrom

http://www.w3.org/2001/XMLSchema#string

John F Seymour

http://www.w3.org/2001/XMLSchema#string

John M Bennett

http://www.w3.org/2001/XMLSchema#string

Lewis R Silverman

http://www.w3.org/2001/XMLSchema#string

Linda Zimmerman

http://www.w3.org/2001/XMLSchema#string

P2860

Proposals for the classification of the myelodysplastic syndromes

International scoring system for evaluating prognosis in myelodysplastic syndromes

Myelodysplastic syndromes.

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

Evaluation of survival data and two new rank order statistics arising in its consideration.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.

Allogeneic stem cell transplantation for myelodysplastic syndrome.

P304

223-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

606811

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S1470-2045(09)70003-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Eva Hellström-Lindberg

Guillermo F Sanz

Valeria Santini

Norbert Gattermann

Aristoteles A N Giagounidis

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24028626

http://www.w3.org/2001/XMLSchema#string

P698

19230772

http://www.w3.org/2001/XMLSchema#string

P932

4086808

http://www.w3.org/2001/XMLSchema#string